{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:07:10Z","timestamp":1774566430401,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"DOI":"10.7759\/cureus.101908","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:23:06Z","timestamp":1768922586000},"source":"Crossref","is-referenced-by-count":2,"title":["Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report"],"prefix":"10.7759","author":[{"given":"Shao Chi","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsing Jung","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"Gudzune KA","year":"2024","unstructured":"Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024, 332:571-84. 10.1001\/jama.2024.10816","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann NC","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023, 25:18-35. 10.1111\/dom.14863","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz A","year":"2024","unstructured":"Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ. Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Am J Cardiol. 2024, 222:121-30. 10.1016\/j.amjcard.2024.04.041","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69844","article-title":"Acute pancreatitis likely due to semaglutide","volume":"16","author":"Hughes K","year":"2024","unstructured":"Hughes K, Sumaruth YR, Mohammed E, Sant Bakshsingh V. Acute pancreatitis likely due to semaglutide. Cureus. 2024, 16:e69844. 10.7759\/cureus.69844","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43773","article-title":"Acute pancreatitis in a patient taking semaglutide","volume":"15","author":"Patel F","year":"2023","unstructured":"Patel F, Gan A, Chang K, Vega KJ. Acute pancreatitis in a patient taking semaglutide. Cureus. 2023, 15:e43773. 10.7759\/cureus.43773","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.endien.2024.03.012","article-title":"Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis","volume":"71","author":"Masson W","year":"2024","unstructured":"Masson W, Lobo M, Barbagelata L, Lavalle-Cobo A, Nogueira JP. Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis. Endocrinol Diabetes Nutr (Engl Ed). 2024, 71:124-32. 10.1016\/j.endien.2024.03.012","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","volume":"40","author":"Pratley R","year":"2024","unstructured":"Pratley R, Saeed ZI, Casu A. Incretin mimetics and acute pancreatitis: enemy or innocent bystander?. Curr Opin Gastroenterol. 2024, 40:404-12. 10.1097\/MOG.0000000000001057","journal-title":"Curr Opin Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis","volume":"37","author":"Tan HC","year":"2022","unstructured":"Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022, 37:65-72. 10.15605\/jafes.037.02.14","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra L","year":"2023","unstructured":"Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023, 17:102834. 10.1016\/j.dsx.2023.102834","journal-title":"Diabetes Metab Syndr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda VR","year":"2023","unstructured":"Aroda VR, Erhan U, Jelnes P, et al.. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023, 25:1385-97. 10.1111\/dom.14990","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003525","article-title":"Glucagon-like peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type 2 diabetes who develop acute pancreatitis: a multicenter analysis","author":"Nieto LM","year":"2025","unstructured":"Nieto LM, Martinez J, Narvaez SI, Ko D, Kim DH, Vega KJ, Chawla S. Glucagon-like peptide-1 receptor agonists use does not increase the risk for acute pancreatitis and is associated with lower complications in patients with type 2 diabetes who develop acute pancreatitis: a multicenter analysis. Am J Gastroenterol. 2025, 10.14309\/ajg.0000000000003525","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2025.06.018","article-title":"Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management","volume":"25","author":"Postlethwaite R","year":"2025","unstructured":"Postlethwaite R, Amin AM, Alsawas R, Almandoz JP, Sawas T. Predictors of acute pancreatitis in patients treated with GLP-1 receptor agonists for weight management. Pancreatology. 2025, 25:609-13. 10.1016\/j.pan.2025.06.018","journal-title":"Pancreatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-0100","article-title":"Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study","volume":"41","author":"Yaseen A","year":"2023","unstructured":"Yaseen A, Lahiri SW. Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study. Clin Diabetes. 2023, 41:490-501. 10.2337\/cd22-0100","journal-title":"Clin Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4735","article-title":"Uptake of and disparities in semaglutide and tirzepatide prescribing for obesity in the US","volume":"333","author":"Kim C","year":"2025","unstructured":"Kim C, Ross JS, Jastreboff AM, Meeker D, Freedman H, Krumholz HM, Lu Y. Uptake of and disparities in semaglutide and tirzepatide prescribing for obesity in the US. JAMA. 2025, 333:2203-6. 10.1001\/jama.2025.4735","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00376-4","article-title":"Multimorbidity","volume":"8","author":"Skou ST","year":"2022","unstructured":"Skou ST, Mair FS, Fortin M, et al.. Multimorbidity. Nat Rev Dis Primers. 2022, 8:48. 10.1038\/s41572-022-00376-4","journal-title":"Nat Rev Dis Primers"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07198-2","article-title":"Prevalent multimorbidity combinations among middle-aged and older adults seen in community health centers","volume":"37","author":"Qui\u00f1ones AR","year":"2022","unstructured":"Qui\u00f1ones AR, Valenzuela SH, Huguet N, et al.. Prevalent multimorbidity combinations among middle-aged and older adults seen in community health centers. J Gen Intern Med. 2022, 37:3545-53. 10.1007\/s11606-021-07198-2","journal-title":"J Gen Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69704","article-title":"Semaglutide-induced acute pancreatitis leading to death after four years of use","volume":"16","author":"Dagher C","year":"2024","unstructured":"Dagher C, Jailani M, Akiki M, Siddique T, Saleh Z, Nadler E. Semaglutide-induced acute pancreatitis leading to death after four years of use. Cureus. 2024, 16:e69704. 10.7759\/cureus.69704","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001579","article-title":"Semaglutide-associated gastric pneumatosis","volume":"12","author":"Turunen AM","year":"2025","unstructured":"Turunen AM, Coombs RA, Garg SK. Semaglutide-associated gastric pneumatosis. ACG Case Rep J. 2025, 12:e01579. 10.14309\/crj.0000000000001579","journal-title":"ACG Case Rep J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/429010-acute-pancreatitis-associated-with-semaglutide-in-a-patient-with-multimorbidity-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:23:06Z","timestamp":1768922586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/429010-acute-pancreatitis-associated-with-semaglutide-in-a-patient-with-multimorbidity-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.101908","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}